Business Wire

Manhattan Pioneers Use of GenAI in Supply Chain Commerce

Share

Manhattan Associates (NASDAQ: MANH) today announced Manhattan Active® Maven, a specialized Generative Artificial Intelligence (GenAI) solution built for customer service, along with Manhattan Assist, which adds cutting-edge GenAI capabilities to all Manhattan Active solutions. The company is applying this state-of-the-art technology to revolutionize consumer interactions, as well as enhancing how Manhattan's customers engage with their solutions.

The new Manhattan Active Maven harnesses the power of GenAI technology to elevate customer experience while simultaneously reducing operational costs. This innovative solution offers a GenAI-powered chatbot for consumers, and a collection of GenAI features aimed at enhancing the efficiency and service standards of customer service representatives. Natively built within Manhattan's industry-leading omnichannel commerce solution, Manhattan Active Maven stands out as the first GenAI-powered customer service chatbot with native access to orders, payments, store locations, and product availability.

Manhattan has leveraged advancements in large language models (LLMs) to reimagine the chatbot experience for pre- and post-purchase experiences. Manhattan Active Maven crafts personalized responses that are dynamic and contextual, akin to those delivered by human agents. Manhattan Active Maven is also incredibly easy to implement. No rules, scripts or integrations are required. Retailers simply embed it on their website, and the solution goes to work.

“GenAI is one of the most exciting technologies we’ve seen in years, and it promises to redefine customer service experiences,” said Ellie Crawford, director of Product Management for Manhattan Associates. “Manhattan Active Maven and Manhattan Assist represent an exciting application of this technology in supply chain and commerce, delivering new levels of personalization, productivity, and cost-savings.”

Manhattan is also announcing Manhattan Assist, a GenAI-powered assistant that provides contextual responses to any questions regarding product functionality, API structures, and more. Manhattan Assist will also provide a natural language summary of how Manhattan Active applications are currently configured. Included with all Manhattan Active Solution subscriptions, this new feature provides platform-level assistance across multiple personas, roles, and functions.

About Manhattan Associates

Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.

Manhattan Associates designs, builds and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.

Receive up-to-date product, customer and partner news directly from Manhattan Associates on X, LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

James Canham-Ash
jash@manh.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB OneSubsea Awarded Contract for Phase 3, Stage 2 of Equinor’s North Sea Troll Project24.5.2024 15:00:00 EEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524523658/en/ SLB OneSubsea is leveraging North Sea compliant, configurable equipment for Equinor’s North Sea Troll project. (Photo: Business Wire) SLB (NYSE: SLB) has announced the award of a sizeable contract by Equinor to its OneSubsea™ joint venture. The award leverages an existing long-term contract for the execution of the second stage of Phase 3 for Equinor’s Troll project in the North Sea, offshore Norway. To accelerate field delivery of the subsea tieback to existing infrastructure, SLB OneSubsea will leverage configurable solutions compliant with NCS2017+ for standardized subsea production systems for application in the Norwegian Continental Shelf (NCS). The objective for Troll Phase 3, Stage 2 is to accelerate production from the reservoir equivalent to about 55 billion standard cubic meters of gas. “We deeply appreciate our long-standing relations

Alipay Supports Xi’an to Build “International Consumer Friendly Tourist Destination”24.5.2024 14:15:00 EEST | Press release

Alipay, the leading digital payment and lifestyle service platform, today announced that it is working with Xi’an, the world-renowned ancient capital city located in Shaanxi province famous for the Terracotta Warriors, to launch the “International Consumer Friendly Tourist Destination” initiative. With the resurgence of inbound tourism to China, the initiative aims to enhance the travel and shopping experiences of international visitors to Xi’an and boost the city’s tourism industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524320945/en/ Launch ceremony of “International Consumer Friendly Tourist Destination” Xi’an (Photo: Business Wire) Alipay – with the support and guidance of local authorities – is working with its partners in Xi’an, including tourist attractions, hotels, restaurants, and public transit agencies, to upgrade their payment and digital services for international travelers. International visitors can

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO ®24.5.2024 13:05:00 EEST | Press release

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test in racially and ethnically diverse patients. Exact Sciences will also present data on its approach to multi-cancer early detection (MCED) across multiple tumor types, plus additional real-world evidence showing optimized screening adherence strategies for the Cologuard® test as well as high adherence rates for repeat screenings. “Exact Sciences’ growing evidence shows that earlier and more personalized treatment interventions lead to greater success for people living with cancer. Therefore, effective cancer screening and di

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia ® and Xgeva ® (denosumab) Biosimilar Candidate HLX1424.5.2024 13:00:00 EEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia® and Xgeva® (denosumab) biosimilar. Denosumab has been approved in various countries and regions under different trade names for a range of different indications such as for the treatment of osteoporosis in postmenopausal women at high risk for fracture, among others. In 2019, it was estimated that 32 million Europeans ages 50 or above had osteoporosis, 25.5 million of which were women.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524114174/en/ The submissions were based on a randomized, double-blind, international multicenter, parallel-controlled phase 3 clinical study that aimed to compare the efficacy, safety, tolerability, and immunogenicity of HLX14 with EU-sourced reference denosumab (Prolia) in

SERES Unveils the MF Platform to Transform Luxury Vehicles With Intelligent Technology24.5.2024 12:00:00 EEST | Press release

Chinese new energy vehicle company SERES Auto has launched its MF platform for intelligent luxury vehicles. The new platform is designed to integrate technologies across safety, power, chassis, and software systems, enabling SERES to respond to dynamic market demands and consumer expectations. "SERES Group's development is rooted in a 'user-centric' approach, focusing on software-defined vehicles," said Zhang Xinghai, Founder and Chairman of SERES Auto. "We will continue to advance our leadership in technology, and further collaborate with global business partners to provide SERES users all over the world with an ultimate experience throughout the entire lifecycle of vehicle use." SERES MF platform’s key features span four key areas, notably safety, power, versatility, and intelligence. The MF platform's safety features cover over 150 scenarios with more than 200 safety features and incorporate 40 safety technologies. Diverse power options are also a part of the MF platform, which is c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye